WBIO Stock Overview
WPD Pharmaceuticals Inc., a biotechnology research and development company, engages in the research and development of medicinal products in the fields of oncology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
WPD Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.045 |
| 52 Week High | CA$0.12 |
| 52 Week Low | CA$0.035 |
| Beta | 1.23 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -92.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| WBIO | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | -7.4% | -1.9% |
| 1Y | 0% | -36.3% | 3.7% |
Return vs Industry: WBIO underperformed the Canadian Biotechs industry which returned 20.4% over the past year.
Return vs Market: WBIO matched the Canadian Market which returned -0.7% over the past year.
Price Volatility
| WBIO volatility | |
|---|---|
| WBIO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 13.8% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: WBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine WBIO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 19 | Mariusz Olejniczak | www.wpdpharmaceuticals.com |
WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company’s drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML.
WPD Pharmaceuticals Inc. Fundamentals Summary
| WBIO fundamental statistics | |
|---|---|
| Market cap | CA$5.10m |
| Earnings (TTM) | -CA$4.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs WBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WBIO income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$1.97k |
| Gross Profit | -CA$1.96k |
| Other Expenses | CA$4.86m |
| Earnings | -CA$4.86m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.043 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -14.4% |
How did WBIO perform over the long term?
See historical performance and comparison